But maybe Edgar to start with you and with your expertise in the condition of autosomal dominant polycystic kidney disease, ...

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused ...

Abnormal kinase signaling can promote other harmful traits, such as neuroinflammation and neuronal cell death. On the other ...

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP ...

A number of the Dutch firm's products have received certification under Europe's In Vitro Diagnostic Regulation recently.

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of ...

Lupin receives USFDA approval for its generic version of Tolvaptan tablets, indicated for autosomal dominant polycystic ...

Advancium Health Network, a public charity dedicated to advancing therapies for rare diseases, has awarded two major grants ...